Provided by Tiger Fintech (Singapore) Pte. Ltd.

Beam Therapeutics, Inc.

19.87
+0.74003.87%
Volume:2.13M
Turnover:43.18M
Market Cap:2.00B
PE:-4.34
High:20.81
Open:20.00
Low:19.85
Close:19.13
Loading ...

Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial

Benzinga
·
06 Nov 2024

Beam could see significant upside over next 6-12 months, says Wedbush

TIPRANKS
·
06 Nov 2024

BUZZ-Beam Therapeutics falls after patient death in early trial

Reuters
·
05 Nov 2024

Buy Rating Affirmed for Beam Therapeutics Due to Promising BEAM-101 Developments in Sickle Cell Disease Treatment

TIPRANKS
·
05 Nov 2024

Beam says patient death determined by investigator to be unrelated to BEAM-101

TIPRANKS
·
05 Nov 2024

Beam Therapeutics to present data on BEAM-101, BEAM-201 at ASH meeting

TIPRANKS
·
05 Nov 2024

Beam Therapeutics' Q3 Net Loss Narrows, Revenue Falls

MT Newswires Live
·
05 Nov 2024

Press Release: Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting

Dow Jones
·
05 Nov 2024

Stock Track | Beam Therapeutics Plunges 17.69% Pre-Market After Mixed Q3 Results and Clinical Trial Updates

Stock Track
·
05 Nov 2024

Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates

Zacks
·
05 Nov 2024

Beam Therapeutics GAAP EPS of -$1.17 misses by $0.02, revenue of $14.27M beats by $0.14M

seekingalpha
·
05 Nov 2024

Beam Therapeutics Ended Third Quarter 2024 With $925.8M In Cash, Cash Equivalents and Marketable Securities; Expected Operating Runway into 2027

Benzinga
·
05 Nov 2024

Beam Therapeutics Inc - Expected Operating Runway Into 2027

THOMSON REUTERS
·
05 Nov 2024

Beam Therapeutics Inc: Qtrly Loss per Shr $1.17

THOMSON REUTERS
·
05 Nov 2024

Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs

THOMSON REUTERS
·
05 Nov 2024

Beam Therapeutics Q3 Operating Expenses USD 120.773 Million

THOMSON REUTERS
·
05 Nov 2024

Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs

GlobeNewswire
·
05 Nov 2024

Cathie Wood's Latest Shake-up: Dumps Palantir And Jack Dorsey's Block Along With Tesla, Buys Amazon And Meta

Benzinga
·
05 Nov 2024

Watch Out: 5 Altcoins in South Korea See Trading Volume Boom – Here’s the List

CoinMarketCap
·
03 Nov 2024

Beam Therapeutics (BEAM): Promising Gene Editing Stock with Base Editing Technology

Insider Monkey
·
31 Oct 2024